As DiMarchi says, 'You really needed something like an epinephrine pen' (Phelan
A few other states are planning or considering obesity drug restrictions in state fiscal year 2026 or 2027, and state interest in expanding coverage of obesity drugs is also waning according to this years survey, with states continuing to report cost as the key factor contributing to obesity drug coverage decisions
Studies show that GLP-1 agonists improve insulin secretion and reduce glucagon levels, which results in better glucose control
While alcohol use on a GLP-1 may be okay, the choice carries some theoretical risks, including reduced weight loss potential and possibly worsened side effects of GLP-1s
Another oral GLP-1 drug, orforglipron (Foundayo) has just been approved by the FDA for weight management
This isn't just paperwork